Detalhe da pesquisa
1.
Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer.
Int J Mol Sci
; 24(11)2023 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37298380
2.
Immunotherapy partners after progression: Right place, right time?
Cancer
; 129(2): 181-183, 2023 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36420775
3.
Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings.
Oncologist
; 21(10): 1250-1259, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27412393
4.
The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature.
Future Oncol
; 10(14): 2189-99, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25471033
5.
Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials.
Int J Radiat Oncol Biol Phys
; 118(5): 1519-1530, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38199382
6.
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.
J Med Econ
; 27(1): 292-303, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38391239
7.
A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors.
JTO Clin Res Rep
; 5(2): 100619, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38328473
8.
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial.
Nat Med
; 30(1): 265-270, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38177853
9.
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
J Thorac Oncol
; 2024 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38461929
10.
The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project.
Cancer Med
; 13(9): e7159, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38741546
11.
ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards.
Lancet Oncol
; 18(12): 1555-1556, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29074100
12.
The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications.
Cancers (Basel)
; 15(11)2023 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37296959
13.
Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis.
Respir Med
; 217: 107330, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37385460
14.
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
Ther Adv Med Oncol
; 15: 17588359231198446, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37720499
15.
STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer.
JCO Precis Oncol
; 7: e2200273, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36603171
16.
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
Neurooncol Adv
; 5(1): vdac183, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36814898
17.
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).
Lung Cancer
; 186: 107423, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37995456
18.
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Cancer Discov
; 13(7): 1556-1571, 2023 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068173
19.
Meeting an un-MET need: Targeting MET in non-small cell lung cancer.
Front Oncol
; 12: 1004198, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36338701
20.
Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer.
Clin Lung Cancer
; 23(5): e317-e320, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35613998